Fig. S1 PIPKI is highly expressed in cancer cell lines

Slides:

Advertisements

Similar presentations

Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice.

Advertisements

EGFR Mutation Testing From the Pathologist’s Point of View

Age, SexHistologyPredominant subtype Pathological stage EGFR mutation CAF1 61, MaleAdenocarcinoma Solid predominant pT3N2M0 L858R CAF2 71, MaleAdenocarcinoma.

Supplementary table 1 miR-506 expression and clinocopathological factors FactorsTotal number miR-506 low expressionmiR-506 high expression P-value (n =

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Main Figures and Tables

EGFR mutation in Austrian patients with NSCLC: a retrospective study

Volume 206, Issue 3, Pages (March 2013)

Large cell undifferentiated carcinoma of lung

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Figure 3. Representative pyrosequencing results for EGFR gene mutations. (A) Case with 10.9% mutation frequency for the L858R mutation in EGFR exon 21.

Lung squamous cell carcinoma

Fig 1A. Patient enrollment flow chart

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognosis of younger patients in non-small cell lung cancer

QUESTIONS OF LUNG CANCER

Patient Case 1 Patient Case 1: PET/CT Scan.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Covariate AD N (%) SCC N (%) p-values Sex 63/63 96/ M

Department of Surgery, Taipei Veterans General Hospital Huang Kuo-Hung

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Red: stable co-clustering Blue: no co-clustering

E13-01: Insights into thymic epithelial tumor: pathology

RET Mutation and Expression in Small-Cell Lung Cancer

Volume 9, Issue 6, Pages (June 2006)

Carcinomas of lung By: Shefaa’ Qa’qa’.

E-cadherin expression associated with differentiation and prognosis in patients with non–small cell lung cancer Dage Liu, MD, Cheng-long Huang, MD, Kotaro.

Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

Volume 9, Issue 6, Pages (June 2006)

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers Carla Verri, MSc, Cristina Borzi, MSc, Todd Holscher,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Head and Neck Cancer 5 Year follow up Audit of patient outcomes

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 5 EGFR mutation status of patients with NSCLC, detected by histological examination and ARMS PCR. EGFR mutation status of patients with NSCLC, detected.

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non-small-cell lung cancer Yukito Ichinose, MDa, Tokujiro.

CT Characteristics and Pathologic Basis of Solitary Cystic Lung Cancer

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

Clinicopathologic Features and Computed Tomographic Findings of 52 Surgically Resected Adenosquamous Carcinomas of the Lung Yukio Watanabe, MD, Koji.

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

Carcinoma of the esophagus: Prognostic significance of histologic type

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Trends in survival from metastatic lung cancer in California,

Figure S1. A. B. Figure S1. Kaplan-Meier curve of progression-free survival by treatment group in soluble heregulin (HRG)-high population (A) and soluble.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Patients’ characteristics

CHCHD2 and EGFR protein expression in NSCLC

Representative CT and PET/CT images of three patients with NSCLCs

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

H & E = hematoxylin and eosin.

Epidermal Growth Factor Receptor Gene Mutation and Computed Tomographic Findings in Peripheral Pulmonary Adenocarcinoma Motoki Yano, MD, PhD, Hidefumi.

DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.

Presentation transcript:

Fig. S1 PIPKI is highly expressed in cancer cell lines Actin B2B H358 H441 PC9 H1975 A549 H1299 H460 SPC-A1 95D B PIPKI Actin siNC siI-1 siI-2 siI-3 C

Fig. S2 Smurf1 degrades PIPKI B + + Flag-Smurf1 PIPKIi2 PIPKIi1 GFP HA-PIPKI Flag-Smurf1 + + Flag-Smurf1 HA-PIPKIi2 HA-PIPKIi2 KD GFP Flag-Smurf1

Fig. S3 Smurf1 interacts with PIPKI B HA-PIPKIi2 - + - - - Flag-Smurf1 HA-PIPKI IP: HA WCE HA-PIPKIi1 - - + - - HA-PIPKIa - - - + - HA-PIPKIb - - - - + GFP-Ii2 WT - + - - GFP-PIPKIi2 IP: GFP WCE F-Smurf1 Talin GFP-Ii2 S650D - - - + GFP-Ii2 S650A - - + - C HA-PIPKIi2 - + - + F-Smurf1 WT HA-PIPKIi2 IP: HA WCE F-Smurf1 T306D

Fig. S4 Lys-255 in PIPKIi2 is important for interacting with Smurf1 B HA-PIPKIi2 WT - + - HA-PIPKIi2 K255R - - + F-Smurf1CA HA-PIPKIi2 IP: HA WCE HA-PIPKIi2 WT - + - HA-PIPKIi2 K255R - - + F-talin Head Flag-talin head HA-PIPKIi2 IP: HA WCE

Fig. S5 Smurf1 phosphorylation by PKA prevents Smurf1-mediated PIPKIg degradation

Supplementary table 1: PIPKI is highly expressed in adenocarcinoma and squamous carcinoma. Table1. Analysis of the association between PIPKI expression in membrane and clinicopathological features in NSCLC PIPKI Number Positive p-value Sex Male 77 28（36.3%） Female 46 14(30.4%) 0.502 Tabacco use Non-smoking 60 20(33.3%) Smoking 63 22(35%) 0.293 Pathology Adenocarcinoma 75 21(28%) Squamous carcinoma 48 19(39.6%) 0.151 Tumor size ≥3cm 70 27(38.6%) <3cm 53 14(26.4%) 0.178 N-status N0 13(18.6%) N1-2 28(52.8%) <0.0001 Stage Ⅰ 51 9(17.6%) Ⅱ 24 6(25%) Ⅲ 43 24(55.8%) Ⅳ 5 3(60%) 0.001 Histologic differentiation Poor 24(50%) Well/Moderate 17(22.7%) 0.002 Lympho-vascular invasion Absent 93 27(29.0%) Present 30 14(46.7%) <0.00001 Pleural invasion 38 14(36.8%) 85 27(31.8%) 0.611

Mutations Identified, n (%) Table 2 Distribution and Frequency of Mutations in adenocarcinoma Mutations Identified, n (%) ASC (n=72) 95% CI (%) EGFR exon 19 deletion 20(27.8%) 17.8-39.5 EGFR L858R 21(29.2%) 19-41 EGFR L861Q 2(2.8%) 0.3-9.1 other mutationsa EGFR wild type 27(37.5%) 26.4-49.7 aIncluded two double EGFR mutation, one was G719C,S768I and the other was S768I,G719A Table3 The association of PIPKI expression and EGFR mutation status in adenocarcinoma of lung Total(n=72) EGFR Mut. p-value PIPKI(+) 51 36(70.6%) PIPKI(-) 21 9(42.8%) 0.027